Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

Authors: Michael C. Heinrich, Jean-Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John R. Zalcberg, Robin L. Jones, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, David Goldstein, César Sánchez, Brittany L. Siontis, Paulina Cox, Erika Davis, Matthew L. Sherman, Rodrigo Ruiz-Soto, Sebastian Bauer

Published: 2025-05-23

DOI: 10.1200/jco-24-02818

Source: Full article

---

Abstract

In the INTRIGUE phase III trial (ClinicalTrials.gov identifier: